

31st October, 2025

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, C-1,
Block- G, Bandra – Kurla Complex,
Bandra (East), Mumbai – 400051
Symbol: AAKAAR

Dear Sir/ Madam,

Sub.: Board Meeting to consider and approve the unaudited financial results for the half year ended September 30, 2025

Pursuant to Regulation 29(1)(a) read with Regulation 50 (1) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [*“Listing Regulation”*], Schedule B of Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 along with Company’s Code of Conduct [*“Code”*], we are pleased to inform you the following:

A. Board Meeting:

A meeting of the Board of Directors of the Company will be held on Monday, November 10, 2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the half year ended September 30, 2025.

B. Trading Window:

In view of declaration of the said results, the ‘Trading Window’ for dealing in securities of the Company shall remain closed:

- From: Wednesday, October 1, 2025
- To: Wednesday, November 12, 2025 [*i.e. 48hrs post declaration of said results*]
[both days inclusive]

The above information has already been duly communicated to your exchange vide our letter dated September 25, 2025 and also to all Designated Persons under the Code.

C. Earnings Conference Call:

The Company will hold an Earnings Conference call to discuss the said results. Details of the call will be intimated in due course.

The above information is available on the website of the Company i.e. www.akaarmedical.in

Thanking you.

Yours faithfully,
For Aakaar Medical Technologies Ltd.

Anoopkumar Pillai
Company Secretary and Compliance Officer